Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; Cetuximab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms AFACET
- 12 Jun 2019 Status changed from active, no longer recruiting to recruiting.
- 07 Dec 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 12 Nov 2018 New trial record